Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention
- 1 July 1999
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 138 (1) , 49-54
- https://doi.org/10.1016/s0002-8703(99)70245-0
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary AngioplastyCirculation, 1997
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 1997
- Tissue Factor Modulates the Thrombogenicity of Human Atherosclerotic PlaquesCirculation, 1997
- Identification of Active Tissue Factor in Human Coronary AtheromaCirculation, 1996
- Management of restenosis after coronary interventionAmerican Heart Journal, 1996
- Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque ruptureJournal of the American College of Cardiology, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.Journal of Clinical Investigation, 1985